|
1
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Charafe-Jauffret E, Ginestier C and
Birnbaum D: Breast cancer stem cells: Tools and models to rely on.
BMC Cancer. 9:2022009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Creighton CJ, Li X, Landis M, Dixon JM,
Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A,
Herschkowitz JI, et al: Residual breast cancers after conventional
therapy display mesenchymal as well as tumor-initiating features.
Proc Natl Acad Sci USA. 106:13820–13825. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gupta PB, Chaffer CL and Weinberg RA:
Cancer stem cells: Mirage or reality? Nat Med. 15:1010–1012. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Frank NY, Schatton T and Frank MH: The
therapeutic promise of the cancer stem cell concept. J Clin Invest.
120:41–50. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Peter ME, Hadji A, Murmann AE, Brockway S,
Putzbach W, Pattanayak A and Ceppi P: The role of CD95 and CD95
ligand in cancer. Cell Death Differ. 22:885–886. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ogasawara J, Watanabe-Fukunaga R, Adachi
M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T and Nagata S:
Lethal effect of the anti-Fas antibody in mice. Nature.
364:806–809. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Martin-Villalba A, Llorens-Bobadilla E and
Wollny D: CD95 in cancer: Tool or target? Trends Mol Med.
19:329–335. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen L, Park SM, Tumanov AV, Hau A, Sawada
K, Feig C, Turner JR, Fu YX, Romero IL, Lengyel E, et al: CD95
promotes tumour growth. Nature. 465:492–496. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Desbarats J and Newell MK: Fas engagement
accelerates liver regeneration after partial hepatectomy. Nat Med.
6:920–923. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jarad G, Wang B, Khan S, DeVore J, Miao H,
Wu K, Nishimura SL, Wible BA, Konieczkowski M, Sedor JR, et al: Fas
activation induces renal tubular epithelial cell beta 8 integrin
expression and function in the absence of apoptosis. J Biol Chem.
277:47826–47833. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Desbarats J, Birge RB, Mimouni-Rongy M,
Weinstein DE, Palerme JS and Newell MK: Fas engagement induces
neurite growth through ERK activation and p35 upregulation. Nat
Cell Biol. 5:118–125. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zuliani C, Kleber S, Klussmann S, Wenger
T, Kenzelmann M, Schreglmann N, Martinez A, del Rio JA, Soriano E,
Vodrazka P, et al: Control of neuronal branching by the death
receptor CD95 (Fas/Apo-1). Cell Death Differ. 13:31–40. 2006.
View Article : Google Scholar
|
|
14
|
Corsini NS, Sancho-Martinez I, Laudenklos
S, Glagow D, Kumar S, Letellier E, Koch P, Teodorczyk M, Kleber S,
Klussmann S, et al: The death receptor CD95 activates adult neural
stem cells for working memory formation and brain repair. Cell Stem
Cell. 5:178–190. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Siegmund D, Lang I and Wajant H: Cell
death-independent activities of the death receptors CD95, TRAILR1,
and TRAILR2. FEBS J. 284:1131–1159. 2017. View Article : Google Scholar
|
|
16
|
Ceppi P, Hadji A, Kohlhapp FJ, Pattanayak
A, Hau A, Liu X, Liu H, Murmann AE and Peter ME: CD95 and CD95L
promote and protect cancer stem cells. Nat Commun. 5:52382014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Teodorczyk M, Kleber S, Wollny D, Sefrin
JP, Aykut B, Mateos A, Herhaus P, Sancho-Martinez I, Hill O,
Gieffers C, et al: CD95 promotes metastatic spread via Sck in
pancreatic ductal adenocarcinoma. Cell Death Differ. 22:1192–1202.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Drachsler M, Kleber S, Mateos A, Volk K,
Mohr N, Chen S, Cirovic B, Tüttenberg J, Gieffers C, Sykora J, et
al: CD95 maintains stem cell-like and non-classical EMT programs in
primary human glioblastoma cells. Cell Death Dis. 7:e22092016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li H, Fan X, Stoicov C, Liu JH, Zubair S,
Tsai E, Ste Marie R, Wang TC, Lyle S, Kurt-Jones E, et al: Human
and mouse colon cancer utilizes CD95 signaling for local growth and
metastatic spread to liver. Gastroenterology. 137:934–944.
944.e931–934. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hoogwater FJ, Nijkamp MW, Smakman N,
Steller EJ, Emmink BL, Westendorp BF, Raats DA, Sprick MR, Schaefer
U, Van Houdt WJ, et al: Oncogenic K-Ras turns death receptors into
metastasis-promoting receptors in human and mouse colorectal cancer
cells. Gastroenterology. 138:2357–2367. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kykalos S, Mathaiou S, Karayiannakis AJ,
Patsouras D, Lambropoulou M and Simopoulos C: Tissue expression of
the proteins fas and fas ligand in colorectal cancer and liver
metastases. J Gastrointest Cancer. 43:224–228. 2012. View Article : Google Scholar
|
|
22
|
Nijkamp MW, Hoogwater FJ, Steller EJ,
Westendorp BF, van der Meulen TA, Leenders MW, Borel Rinkes IH and
Kranenburg O: CD95 is a key mediator of invasion and accelerated
outgrowth of mouse colorectal liver metastases following
radiofrequency ablation. J Hepatol. 53:1069–1077. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sträter J, Hinz U, Hasel C, Bhanot U,
Mechtersheimer G, Lehnert T and Möller P: Impaired CD95 expression
predisposes for recurrence in curatively resected colon carcinoma:
Clinical evidence for immunoselection and CD95L mediated control of
minimal residual disease. Gut. 54:661–665. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang W, Ding EX, Wang Q, Zhu DQ, He J, Li
YL and Wang YH: Fas ligand expression in colon cancer: A possible
mechanism of tumor immune privilege. World J Gastroenterol.
11:3632–3635. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hadji A, Ceppi P, Murmann AE, Brockway S,
Pattanayak A, Bhinder B, Hau A, De Chant S, Parimi V, Kolesza P, et
al: Death induced by CD95 or CD95 ligand elimination. Cell Rep.
7:208–222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Weiswald LB, Bellet D and Dangles-Marie V:
Spherical cancer models in tumor biology. Neoplasia. 17:1–15. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hirschhaeuser F, Menne H, Dittfeld C, West
J, Mueller-Klieser W and Kunz-Schughart LA: Multicellular tumor
spheroids: An underestimated tool is catching up again. J
Biotechnol. 148:3–15. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chandrasekaran S, Marshall JR, Messing JA,
Hsu JW and King MR: TRAIL-mediated apoptosis in breast cancer cells
cultured as 3D spheroids. PLoS One. 9:e1114872014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Endo H, Okami J, Okuyama H, Kumagai T,
Uchida J, Kondo J, Takehara T, Nishizawa Y, Imamura F, Higashiyama
M, et al: Spheroid culture of primary lung cancer cells with
neuregulin 1/HER3 pathway activation. J Thorac Oncol. 8:131–139.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tong JG, Valdes YR, Barrett JW, Bell JC,
Stojdl D, McFadden G, McCart JA, DiMattia GE and Shepherd TG:
Evidence for differential viral oncolytic efficacy in an in vitro
model of epithelial ovarian cancer metastasis. Mol Ther Oncolytics.
2:150132015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qureshi-Baig K, Ullmann P, Rodriguez F,
Frasquilho S, Nazarov PV, Haan S and Letellier E: What do we learn
from spheroid culture systems? Insights from tumorspheres derived
from primary colon cancer tissue. PLoS One. 11:e01460522016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Raats DA, Frenkel N, van Schelven SJ,
Rinkes IH, Laoukili J and Kranenburg O: CD95 ligand induces
senescence in mismatch repair-deficient human colon cancer via
chronic caspase-mediated induction of DNA damage. Cell Death Dis.
8:e26692017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wierzbicki PM, Adrych K, Kartanowicz D,
Stanislawowski M, Kowalczyk A, Godlewski J, Skwierz-Bogdanska I,
Celinski K, Gach T, Kulig J, et al: Underexpression of LATS1 TSG in
colorectal cancer is associated with promoter hypermethylation.
World J Gastroenterol. 19:4363–4373. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
O'Reilly LA1, Tai L, Lee L, Kruse EA,
Grabow S, Fairlie WD, Haynes NM, Tarlinton DM, Zhang JG, Belz GT,
et al: Membrane-bound Fas ligand only is essential for Fas-induced
apoptosis. Nature. 461:659–663. 2009. View Article : Google Scholar
|
|
36
|
Todaro M, Francipane MG, Medema JP and
Stassi G: Colon cancer stem cells: Promise of targeted therapy.
Gastroenterology. 138:2151–2162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schickel R, Park SM, Murmann AE and Peter
ME: miR-200c regulates induction of apoptosis through CD95 by
targeting FAP-1. Mol Cell. 38:908–915. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Steller EJ, Ritsma L, Raats DA, Hoogwater
FJ, Emmink BL, Govaert KM, Laoukili J, Rinkes IH, van Rheenen J and
Kranenburg O: The death receptor CD95 activates the cofilin pathway
to stimulate tumour cell invasion. EMBO Rep. 12:931–937. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hong S, Kim S, Kim HY, Kang M, Jang HH and
Lee WS: Targeting the PI3K signaling pathway in KRAS mutant colon
cancer. Cancer Med. 5:248–255. 2016. View Article : Google Scholar :
|
|
40
|
Élez E, Kocáková I, Höhler T, Martens UM,
Bokemeyer C, Van Cutsem E, Melichar B, Smakal M, Csőszi T, Topuzov
E, et al: Abituzumab combined with cetuximab plus irinotecan versus
cetuximab plus irinotecan alone for patients with KRAS wild-type
metastatic colorectal cancer: The randomised phase I/II POSEIDON
trial. Ann Oncol. 26:132–140. 2015. View Article : Google Scholar
|
|
41
|
Igney FH and Krammer PH: Tumor
counterattack: Fact or fiction? Cancer Immunol Immunother.
54:1127–1136. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
O'Connell J, O'Sullivan GC, Collins JK and
Shanahan F: The Fas counterattack: Fas-mediated T cell killing by
colon cancer cells expressing Fas ligand. J Exp Med. 184:1075–1082.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Igney FH and Krammer PH: Death and
anti-death: Tumour resistance to apoptosis. Nat Rev Cancer.
2:277–288. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hoogwater FJ, Snoeren N, Nijkamp MW,
Gunning AC, van Houdt WJ, DE Bruijn MT, Voest EE, van Hillegersberg
R, Kranenburg O and Rinkes IH: Circulating CD95-ligand as a
potential prognostic marker for recurrence in patients with
synchronous colorectal liver metastases. Anticancer Res.
31:4507–4512. 2011.PubMed/NCBI
|
|
45
|
Konno R, Takano T, Sato S and Yajima A:
Serum soluble fas level as a prognostic factor in patients with
gynecological malignancies. Clin Cancer Res. 6:3576–3580.
2000.PubMed/NCBI
|
